Drugs / SAR442501
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05846009 | Nov 2020 → Jan 2022 | osteochondrodysplasia | Sanofi | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06067425 | Oct 2023 → Feb 2025 | osteochondrodysplasia | Sanofi | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR442501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06067425 ↗ |
| Route | Subcutaneous | “Subcutaneous injection” NCT05846009 ↗ |